CJC-1295 (No DAC) and Kisspeptin-10: What Combination Research Shows
Investigators exploring neuroendocrine signaling pathways frequently examine how discrete peptide axes interact under controlled laboratory conditions. This review synthesizes current preclinical data on the GHRH analog CJC-1295 (No DAC) and the neuroendocrine peptide Kisspeptin-10, outlining their distinct mechanisms, theoretical overlap, assay design parameters, and handling specifications for in vitro and animal models.
Quick answer
Investigators exploring neuroendocrine signaling pathways frequently examine how discrete peptide axes interact under controlled laboratory conditions. This review synthesizes current preclinical data on the GHRH analog CJC-1295 (No DAC) and the neuroendocrine peptide Kisspeptin-10, outlining their distinct mechanisms, theoretical overlap, assay design parameters, and handling specifications for in vitro and animal models.
Key takeaways
- The endocrine system operates through a network of interconnected feedback loops, primarily orchestrated by the hypothalamus and the anterior pituitary gland.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC), also identified as Tetrasubstituted GRF 1-29, is a synthetic peptide analog of growth hormone-releasing hormone (GHRH).
- [Kisspeptin](/research-peptides/kisspeptin-10)-10 is a decapeptide derived from the proteolytic cleavage of the precursor KISS1 gene product.
- The theoretical basis for studying [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC) and [Kisspeptin](/research-peptides/kisspeptin-10)-10 in tandem stems from the observed metabolic and physiological interactions between the growth hormone (somatotropic) and reproductive (gonadotropic) axes.
Introduction to Hypothalamic-Pituitary Axis Co-Exploration
The endocrine system operates through a network of interconnected feedback loops, primarily orchestrated by the hypothalamus and the anterior pituitary gland. In laboratory settings, understanding how these pathways modulate metabolic, regenerative, and reproductive functions requires precise molecular tools. Researchers investigating these complex signaling cascades often utilize targeted synthetic analogs to isolate specific receptor interactions.
Among these tools, combining peptides targeting distinct neuroendocrine pathways allows researchers to study multi-axis cross-talk. Specifically, examining a somatotropic modulator alongside a gonadotropic or hypothalamic regulator provides insights into metabolic signaling integration. This document details the individual biophysical properties, shared receptor dynamics, assay configurations, and biochemical handling standards for investigating CJC-1295 (No DAC) alongside Kisspeptin-10 in preclinical research settings.
Molecular Pharmacodynamics of CJC-1295 (No DAC)
CJC-1295 (No DAC), also identified as Tetrasubstituted GRF 1-29, is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). By substituting specific amino acids at positions 2, 8, 15, and 27 relative to endogenous GHRH, the molecule demonstrates increased resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). This modification extends its biological half-life in vitro and in animal models compared to native GHRH (1-29) fragments.
In laboratory models, CJC-1295 (No DAC) acts as a selective agonist at the GHRH receptor located on pituitary somatotropes. Activation of this G-protein coupled receptor (GPCR) stimulates the intracellular cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) cascades. Preclinical studies suggest that this cascade promotes the pulsatile synthesis and secretion of endogenous growth hormone (GH), which subsequently triggers downstream hepatic synthesis of insulin-like growth factor 1 (IGF-1). Consequently, CJC-1295 (No DAC) is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research.
Receptor Dynamics and Signaling Pathways of Kisspeptin-10
Kisspeptin-10 is a decapeptide derived from the proteolytic cleavage of the precursor KISS1 gene product. It represents the minimal functional sequence required to bind and activate the G-protein coupled receptor KISS1R (formerly known as GPR54). Expressed predominantly within the hypothalamus, KISS1R activation plays a master regulatory role in the hypothalamic-pituitary-gonadal (HPG) axis.
In vitro signaling assays show that Kisspeptin-10 binding to KISS1R couples to the Gq/11 pathway, activating phospholipase C (PLC) and inducing intracellular calcium mobilization along with protein kinase C (PKC) phosphorylation. In animal models, this activation stimulates the pulsatile release of gonadotropin-releasing hormone (GnRH) from hypothalamic neurons, driving downstream secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. Beyond reproductive axis signaling, researchers evaluate Kisspeptin-10 for its roles in cell migration, metabolic homeostasis, and cardiovascular tissue signaling.
Rationale for Dual-Axis Preclinical Investigation
The theoretical basis for studying CJC-1295 (No DAC) and Kisspeptin-10 in tandem stems from the observed metabolic and physiological interactions between the growth hormone (somatotropic) and reproductive (gonadotropic) axes. Energy homeostasis, cellular repair, and reproductive capability are tightly linked biological processes. Under nutrient-deprived or stress-induced states in laboratory models, signaling across both axes exhibits concurrent down-regulation.
By simultaneously probing the GHRH receptor and KISS1R, researchers can investigate how concomitant stimulation of GH/IGF-1 production and GnRH/gonadotropin secretion influences secondary target tissues. Co-exposure assays permit the evaluation of gene expression patterns associated with cellular proliferation, mitochondrial biogenesis, and protein translation without the confounding variables of unmonitored endogenous feedback mechanisms.
Evaluating Preclinical Data and Gaps in Combination Literature
While individual literature detailing CJC-1295 (No DAC) and Kisspeptin-10 is extensive, direct combination data in animal models remain exploratory. Isolated preclinical studies confirm that CJC-1295 (No DAC) elevates serum GH and IGF-1 markers, while independent studies document Kisspeptin-10's capacity to induce rapid LH spikes and modulate cellular motility assays.
Crucially, literature detailing simultaneous administration datasets—such as competitive receptor binding, mutual metabolic clearance alterations, or synergistic intracellular secondary messenger cross-talk—remains sparse. Researchers must recognize that theoretical complementarity between somatotropic and gonadotropic pathways does not substitute for empirical baseline measurements. Current research protocols involving both compounds focus on establishing baseline dose-response profiles in co-cultured cells or dual-cannulated rodent models to map potential receptor crosstalk accurately.
Comparative Analysis with Related Secretagogues and Neuroendocrine Peptides
To properly contextualize research findings, investigators frequently compare CJC-1295 (No DAC) and Kisspeptin-10 against other established compounds within our catalog of research peptides. Within the growth factor secretagogue category, CJC-1295 (No DAC) operates via GHRH receptor activation, whereas ghrelin receptor agonists like Ipamorelin or GHRP-6 target the Growth Hormone Secretagogue Receptor (GHS-R1a). Combining a GHRH analog with a GHS-R agonist is a well-documented approach to evaluate synergistic GH release, presenting a distinct paradigm from pairing a GHRH analog with a KISS1R agonist like Kisspeptin-10.
Similarly, while Kisspeptin-10 acts upstream to trigger endogenous GnRH release, direct GnRH receptor agonists bypass hypothalamic kisspeptin signaling altogether. Comparing these compounds across diverse growth hormone secretagogues allows researchers to isolate central hypothalamic integration mechanisms from direct pituitary receptor stimulation.
In Vitro and Animal Model Assay Design Considerations
When designing in vitro experiments involving both CJC-1295 (No DAC) and Kisspeptin-10, researchers must carefully establish control parameters. Primary pituitary cell cultures or immortalized neuronal lines (such as GT1-7 or LβT2 cells) require defined, serum-free media conditions to prevent background interference from endogenous growth factors or steroid hormones. Time-course assays should account for differing receptor internalization rates: GHRH receptors often undergo rapid desensitization under continuous exposure, whereas KISS1R activation may exhibit distinct pulse-frequency sensitivities.
In vivo animal models (e.g., rodent studies) require consideration of pharmacokinetics and dosing intervals. Because CJC-1295 (No DAC) lacks the Drug Affinity Complex (DAC) modification that binds serum albumin, its circulatory half-life in rodents is measured in minutes to hours rather than days. Kisspeptin-10 similarly exhibits rapid enzymatic degradation in plasma by endopeptidases. Consequently, experimental protocols measuring systemic pulsatile responses often utilize automated blood sampling systems or continuous microinfusion setups.
Laboratory Handling, Solubilization, and Reconstitution Protocols
Proper reconstitution practices are essential to preserve the structural integrity and molar concentrations of both lyophilized peptides. Lyophilized cakes should be brought to room temperature inside a desiccated environment prior to reconstitution to minimize moisture condensation. For precise concentration calculations prior to assay preparation, researchers should utilize a dedicated reconstitution calculator.
It is standard laboratory practice to reconstitute CJC-1295 (No DAC) and Kisspeptin-10 in separate sterile vials using an appropriate solvent, such as sterile bacteriostatic water or phosphate-buffered saline (PBS, pH 7.4), depending on assay requirements. Co-reconstitution into a single stock vial is generally discouraged unless specific short-term stability studies have verified the absence of peptide-peptide aggregation, charge interaction, or accelerated hydrolysis. Once solubilized, stock solutions should be gently swirled rather than vortexed to avoid shear stress-induced denaturation.
Chemical Stability, Storage Conditions, and Degradation Pathways
Lyophilized CJC-1295 (No DAC) and Kisspeptin-10 should be stored at -20°C or -80°C for long-term preservation, shielded from direct light. Under these conditions, the dry peptide matrix remains stable for extended periods. Repeated freeze-thaw cycles must be strictly avoided, as the physical stress of ice crystal formation causes peptide cleavage and aggregation.
After reconstitution, aqueous stock solutions should be aliquoted into single-use polypropylene or low-protein-binding microcentrifuge tubes and stored at -80°C for prolonged study timelines, or at 2°C to 8°C for short-term working use (typically under 7 to 14 days, depending on solvent sterile preservation). Degradation primary pathways include deamidation at asparagine/glutamine residues, oxidation of methionine residues, and peptide bond cleavage via ambient proteases.
Analytical Quality Controls: HPLC, MS, and Endotoxin Testing
Data integrity in preclinical research depends entirely on the chemical purity and consistency of the reagents used. Research compounds must undergo rigorous analytical verification before deployment in cell assays or animal models. Every lot produced for PX1 Research is verified via High-Performance Liquid Chromatography (HPLC) to confirm structural purity exceeds 99%, alongside Mass Spectrometry (MS) to validate exact molecular weight.
In addition to purity metrics, controlling for bacterial contamination is critical. Endotoxin contamination in research peptides can trigger non-specific inflammatory responses in cell culture or animal models, invalidating experimental outcomes. PX1 Research products undergo rigorous Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below established laboratory thresholds. Detailed analytical documentation for every batch is accessible via our Certificate of Analysis (COA) repository, supporting rigorous science across our neuroendocrine research portal and bulk research accounts.
Frequently Asked Questions
What is the primary operational difference between CJC-1295 with DAC and CJC-1295 No DAC?
CJC-1295 with DAC contains a Drug Affinity Complex moiety that covalently binds to circulating serum albumin, extending its biological half-life to several days in animal models. CJC-1295 (No DAC) lacks this complex, resulting in a shorter half-life that allows researchers to study more acute, pulsatile growth hormone release patterns.
What receptor target does Kisspeptin-10 bind to in laboratory models?
Kisspeptin-10 acts as a potent agonist at the KISS1R receptor (formerly known as GPR54), a G-protein coupled receptor located primarily on hypothalamic GnRH neurons.
Is CJC-1295 (No DAC) approved for human clinical use or administration?
No. CJC-1295 (No DAC) is a synthetic research compound intended exclusively for laboratory, in vitro, and preclinical animal research. It is strictly not for human or veterinary use.
Can CJC-1295 (No DAC) and Kisspeptin-10 be reconstituted in the same vial?
Co-reconstitution into a single stock vial is generally discouraged. Reconstituting each lyophilized peptide in separate sterile vials prevents potential physical interactions, solubility shifts, or accelerated degradation, ensuring precise concentration controls in experimental setups.
How should reconstituted stock solutions of these peptides be stored?
Reconstituted solutions should be divided into single-use aliquots to avoid freeze-thaw cycles and stored at -80°C for long-term studies, or at 2°C to 8°C for short-term working protocols (typically under 7–14 days).
What analytical parameters confirm the quality of PX1 Research peptides?
PX1 Research peptides undergo HPLC analysis to ensure >99% chemical purity, Mass Spectrometry to confirm identity, and LAL testing to verify endotoxin levels are safe for sensitive cell culture and in vivo research.
What solvent is recommended for solubilizing CJC-1295 (No DAC) and Kisspeptin-10?
Sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4) are standard diluents. Solvent choice depends on whether the compound will be used in short-term cell culture or longer-term animal microinfusion protocols.
Where can researchers verify batch-specific test results for PX1 products?
Batch-specific analytical data, including HPLC chromatograms and Mass Spectrometry reports, are published in the PX1 Research COA portal available on our site.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.